SCHEMBL30794729

SCHEMBL30794729

COCCCn1c(=O)c(C(=O)NCc2cccc(F)c2)c(C)c2ccc(C(F)(F)F)cc21

nearest known ligand 0.45

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
S1PR3 Q99500 2/20 0.45
ADORA2A P29274 2/20 0.43
PDE10A Q9Y233 1/20 0.43
CCR1 P32246 2/20 0.41
GLS O94925 1/20 0.41
MAPT P10636 2/20 0.41
POLB P06746 1/20 0.41
PPARG P37231 1/20 0.40
ROCK2 O75116 1/20 0.40
TRPV4 Q9HBA0 1/20 0.40
MLYCD O95822 1/20 0.39
ALDH1A1 P00352 1/20 0.39
HPGD P15428 1/20 0.39
ALOX12 P18054 1/20 0.39
HTT P42858 1/20 0.39
SMN1; SMN2 Q16637 1/20 0.39
NPSR1 Q6W5P4 1/20 0.39
LMNA P02545 1/20 0.39
TP53 P04637 1/20 0.39
RXFP1 Q9HBX9 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29862 1.00 S1PR3 (0.45) S1PR3ADORA2APDE10ACCR1GLS
SCHEMBL30795406 0.95 S1PR3 (0.46) S1PR3PDE10ACCR1GLSMAPT
SCHEMBL29501 0.95 S1PR3 (0.46) S1PR3PDE10ACCR1GLSMAPT
SCHEMBL29084 0.92 S1PR3 (0.43) S1PR3PDE10ACCR1GLSMAPT
SCHEMBL30795901 0.92 S1PR3 (0.43) S1PR3PDE10ACCR1GLSMAPT
SCHEMBL29667 0.92 POLB (0.50) S1PR3PDE10ACCR1GLSMAPT
SCHEMBL30795727 0.92 POLB (0.50) S1PR3PDE10ACCR1GLSMAPT
SCHEMBL30795913 0.91 CNR2 (0.47) S1PR3CCR1GLSMAPTPOLB
SCHEMBL29819 0.91 CNR2 (0.47) S1PR3CCR1GLSMAPTPOLB
SCHEMBL714174 0.90 S1PR3 (0.45) S1PR3PDE10ACCR1GLSMAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4584250-A1 COMBINATION THERAPIES INCLUDING METAL CHANNEL ACTIVATORS Biohaven Therapeutics Ltd. (VG) 2025-07-16 EP disclosed
EP-4580679-A1 COMBINATION THERAPIES INCLUDING METAL CHANNEL ACTIVATORS AND NMDA RECEPTOR ANTAGONISTS Biohaven Therapeutics Ltd. (VG) 2025-07-09 EP disclosed
WO-2024054811-A1 COMBINATION THERAPIES INCLUDING METAL CHANNEL ACTIVATORS BIOHAVEN THERAPEUTICS LTD. (VG) 2024-03-14 WO disclosed
WO-2024054807-A1 COMBINATION THERAPIES INCLUDING METAL CHANNEL ACTIVATORS AND TDP-43 MODULATORS BIOHAVEN THERAPEUTICS LTD. (VG) 2024-03-14 WO disclosed
WO-2024050389-A1 COMBINATION THERAPIES INCLUDING METAL CHANNEL ACTIVATORS AND NMDA RECEPTOR ANTAGONISTS BIOHAVEN THERAPEUTICS LTD. (VG) 2024-03-07 WO disclosed